These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 22751546)

  • 1. The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata.
    Shields RK; Nguyen MH; Press EG; Kwa AL; Cheng S; Du C; Clancy CJ
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4862-9. PubMed ID: 22751546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spontaneous Mutational Frequency and
    Shields RK; Kline EG; Healey KR; Kordalewska M; Perlin DS; Nguyen MH; Clancy CJ
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure.
    Shields RK; Nguyen MH; Press EG; Updike CL; Clancy CJ
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3528-35. PubMed ID: 23669387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.
    Alexander BD; Johnson MD; Pfeiffer CD; Jiménez-Ortigosa C; Catania J; Booker R; Castanheira M; Messer SA; Perlin DS; Pfaller MA
    Clin Infect Dis; 2013 Jun; 56(12):1724-32. PubMed ID: 23487382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance.
    Zimbeck AJ; Iqbal N; Ahlquist AM; Farley MM; Harrison LH; Chiller T; Lockhart SR
    Antimicrob Agents Chemother; 2010 Dec; 54(12):5042-7. PubMed ID: 20837754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations.
    Lepak A; Castanheira M; Diekema D; Pfaller M; Andes D
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5875-82. PubMed ID: 22948870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance.
    Pham CD; Iqbal N; Bolden CB; Kuykendall RJ; Harrison LH; Farley MM; Schaffner W; Beldavs ZG; Chiller TM; Park BJ; Cleveland AA; Lockhart SR
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4690-6. PubMed ID: 24890592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia.
    Beyda ND; John J; Kilic A; Alam MJ; Lasco TM; Garey KW
    Clin Infect Dis; 2014 Sep; 59(6):819-25. PubMed ID: 24879785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint.
    Garcia-Effron G; Lee S; Park S; Cleary JD; Perlin DS
    Antimicrob Agents Chemother; 2009 Sep; 53(9):3690-9. PubMed ID: 19546367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro antifungal susceptibility of Candida glabrata to caspofungin and the presence of FKS mutations correlate with treatment response in an immunocompromised murine model of invasive infection.
    Fernández-Silva F; Lackner M; Capilla J; Mayayo E; Sutton D; Castanheira M; Fothergill AW; Lass-Flörl C; Guarro J
    Antimicrob Agents Chemother; 2014 Jul; 58(7):3646-9. PubMed ID: 24733474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.
    Arendrup MC; Perlin DS; Jensen RH; Howard SJ; Goodwin J; Hope W
    Antimicrob Agents Chemother; 2012 May; 56(5):2435-42. PubMed ID: 22354305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of fks1 and fks2 gene mutations in invasive Candida glabrata strains from Pakistan.
    Memon S; Ghanchi NK; Zafar U; Farooqi J; Zaka S; Jabeen K
    Mycoses; 2023 Jan; 66(1):52-58. PubMed ID: 36106428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anidulafungin and micafungin MIC breakpoints are superior to that of caspofungin for identifying FKS mutant Candida glabrata strains and Echinocandin resistance.
    Shields RK; Nguyen MH; Press EG; Updike CL; Clancy CJ
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6361-5. PubMed ID: 24060873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata.
    Pfaller MA; Castanheira M; Lockhart SR; Ahlquist AM; Messer SA; Jones RN
    J Clin Microbiol; 2012 Apr; 50(4):1199-203. PubMed ID: 22278842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breakthrough invasive candidiasis in patients on micafungin.
    Pfeiffer CD; Garcia-Effron G; Zaas AK; Perfect JR; Perlin DS; Alexander BD
    J Clin Microbiol; 2010 Jul; 48(7):2373-80. PubMed ID: 20421445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accuracy of Sensititre YeastOne echinocandins epidemiological cut-off values for identification of FKS mutant Candida albicans and Candida glabrata: a ten year national survey of the Fungal Infection Network of Switzerland (FUNGINOS).
    Kritikos A; Neofytos D; Khanna N; Schreiber PW; Boggian K; Bille J; Schrenzel J; Mühlethaler K; Zbinden R; Bruderer T; Goldenberger D; Pfyffer G; Conen A; Van Delden C; Zimmerli S; Sanglard D; Bachmann D; Marchetti O; Lamoth F;
    Clin Microbiol Infect; 2018 Nov; 24(11):1214.e1-1214.e4. PubMed ID: 29909005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifungal drug susceptibility, molecular basis of resistance to echinocandins and molecular epidemiology of fluconazole resistance among clinical Candida glabrata isolates in Kuwait.
    Al-Baqsami ZF; Ahmad S; Khan Z
    Sci Rep; 2020 Apr; 10(1):6238. PubMed ID: 32277126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical perspectives on echinocandin resistance among Candida species.
    Shields RK; Nguyen MH; Clancy CJ
    Curr Opin Infect Dis; 2015 Dec; 28(6):514-22. PubMed ID: 26524326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rate of FKS Mutations among Consecutive Candida Isolates Causing Bloodstream Infection.
    Shields RK; Nguyen MH; Press EG; Cumbie R; Driscoll E; Pasculle AW; Clancy CJ
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7465-70. PubMed ID: 26392494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discontinuation of echinocandin and azole treatments led to the disappearance of an FKS alteration but not azole resistance during clonal Candida glabrata persistent candidaemia.
    Imbert S; Castain L; Pons A; Jacob S; Meyer I; Palous M; Vezinet C; Langeron O; Hennequin C; Monsel A; Fekkar A
    Clin Microbiol Infect; 2016 Oct; 22(10):891.e5-891.e8. PubMed ID: 27484020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.